Barbara Channer

Barbara Channer has a diverse work experience in the pharmaceutical industry. Barbara is currently the Director Analytical Development Quality Control Drug Substance Clinical & Commercial at Idorsia Pharmaceuticals Ltd since October 2019. Prior to that, they worked as an Associate Director and Senior Manager in Analytical Development Quality Control at Novartis from 2013 to 2018. Barbara also held a role as the Associate Director of Analytical Development and Quality Control at Actelion from 2010 to 2013. Earlier in their career, they worked as a Product Manager at Solvias AG from 2008 to 2010, and as a Senior Scientist and Team Leader at Lonza from 2005 to 2008. Barbara also has previous experience at AstraZeneca, Madaus, Buhler, Dragenopharm Apotheker Pueschl GmbH, and Pereg GmbH.

Barbara Channer holds a Bachelor of Science (BSc) degree in Pharmaceutical Analysis from NTA Isny, which they obtained from 1992 to 1996. Barbara then pursued a Master of Science (MSc) degree in Pharmaceutical Analysis from the University of Strathclyde from 2000 to 2001. Later, they completed their education with a PhD in Pharmaceutical Sciences from the University of Strathclyde between 2001 and 2005. Barbara Channer has also obtained additional certifications, including "USP Standards and Best Practices for Gene Therapy" from the US Pharmacopeia and "CANCER IN THE 21ST CENTURY: THE GENOMIC REVOLUTION" from the University of Glasgow in September 2015.